BARBARA DEPA: Open Payments
NPI 1063135374 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$647 in 52 payments from 9 companies in 2025. Trend: 2023 $837 · 2024 $624 · 2025 $647
Food & beverage: $647
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 11 | $175 |
| ABBVIE INC. | 27 | $171 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $87 |
| Alkermes, Inc. | 3 | $82 |
| Neurocrine BioSciences, Inc. | 2 | $33 |
| Lundbeck LLC | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
Products named: COBENFY, VRAYLAR, CAPLYTA, LYBALVI, INGREZZA, ABILIFY ASIMTUFII, FANAPT, Auvelity.
Industry payments across TX — which companies pay providers there.
